NCT02786615 is a NA clinical trial of Peer Unity in HIV, sponsored by Columbia University.

Who is sponsoring NCT02786615?

NCT02786615 is sponsored by Columbia University.

What drugs are being tested in NCT02786615?

Interventions in NCT02786615: Peer Unity.

What condition does NCT02786615 study?

NCT02786615 studies HIV, Substance-Related Disorders.

Is NCT02786615 still recruiting?

NCT02786615 is currently completed. Last updated 27 May 2022.

Last reviewed 2022-05-27 · How we verify

NCT02786615

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Increasing MSM in the Continuum of Care in Kazakhstan

Completed NA Last updated 27 May 2022

What this trial tests

NA trial testing Peer Unity in HIV in 987 participants. Completed in 30 April 2022.

Timeline

27 June 2018

Primary endpoint
31 March 2022

30 April 2022

Quick facts

Lead sponsor	Columbia University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	health services research
Enrollment	987
Start date	27 June 2018
Primary completion	31 March 2022
Estimated completion	30 April 2022
Sites	2 locations across Kazakhstan, United States

Drugs / interventions tested

Peer Unity

Conditions studied

HIV — all drugs for HIV →
Substance-Related Disorders — all drugs for Substance-Related Disorders →

Sponsor

Columbia University

Who can join

18 and older, male only, with HIV or Substance-Related Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study addresses the disproportionate representation of men who have sex with men (MSM) in the human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) pandemic in Kazakhstan, a country that has seen some of the largest growth in new HIV infections since the turn of the century. Using a stepped wedge trial across 3 cities in Kazakhstan, the proposed study will test a strategic and innovative social network-based intervention for MSM who use drugs in Kazakhstan as a strategy to increase their numbers in the HIV continuum of care.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Compounding vulnerabilities: victimization and discrimination is associated with COVID-19 disruptions to HIV-related care among gay, bisexual, and other men and transgender and nonbinary people who have sex with men in Kazakhstan.
Paine EA, Lee YG, Mergenova G, Vinogradov V, et al · · 2023 · cited 8× · PMID 36628449 · DOI 10.1080/09540121.2022.2148956
Social Impacts of Multi-City HIV Research Participation Among Sexual and Gender Expansive Individuals in Kazakhstan.
Vinogradov V, Lee YG, Zhakupova G, Mergenova G, et al · · 2025 · cited 1× · PMID 39988747 · DOI 10.1097/qai.0000000000003654
Trans Health is Public Health: The Prevalence of HIV Among Trans and Gender Expansive People in Kazakhstan
Reeder KG, Lee YG, Sung J, Vinogradov V, et al · · 2024 · DOI 10.21203/rs.3.rs-5124958/v1
Increasing HIV Testing Among Sexual and Gender Expansive Men in Kazakhstan: A Stepped-Wedge Randomized Trial of a Community-Level Intervention
Wu E, Lee YG, Vinogradov V, Zhakupova G, et al · · 2024 · DOI 10.1101/2024.08.01.24311235

Verify or expand the search:

Other recruiting trials for HIV

Currently open trials in the same condition.

NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · recruiting
NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
NCT07390474 — Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i · Phase 1 · recruiting
NCT07390955 — A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 · Phase 1 · recruiting

Other Columbia University trials

Trials by the same sponsor.

NCT06558422 — Human Models of Selective Insulin Resistance: Pancreatic Clamp · Phase 1 · not yet recruiting
NCT07264582 — HIV/STI/HCV Testing and Overdose Prevention Among Survivors of Sex Trafficking · NA · not yet recruiting
NCT05992415 — Know Your Pressures NYC · NA · not yet recruiting
NCT05645211 — The AgRP and GH/IGF-1 Axis in Children · not yet recruiting
NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02786615 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Columbia University
Last refreshed: 27 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02786615.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing